[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"central-venous-pressure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:central-venous-pressure":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100584110","non-invasive-central-venous-pressure-estimation-in-pediatric-patients-100584110",false,"NCT06885073","Non-invasive Central Venous Pressure Estimation in Pediatric Patients","CPMX-CVP-Ped","Inclusion Criteria\n\n* Provision of signed and dated informed consent form\n* Male or female\n* Age: birth to 21 years of age\n* Equipped with a central venous catheter (CVC) for central venous pressure (CVP) monitoring indication as part of standard of care, or undergoing cardiac catheterization.\n\nExclusion Criteria:\n\n* Weight less than 2.5kg at the time of enrollment.\n* Bilateral external jugular veins not accessible due to vascular access or dressing.\n* Bilateral skin lesion contraindicating neck Ultrasound\n* Active bleeding\n* Clinically unstable, per clinical assessment by attending physician and\u002For surgeon","ALL","21 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","Central Venous Pressure (CVP) is a standard parameter for hemodynamic monitoring and is currently measured through the insertion of a catheter. The pediatric population is especially vulnerable to risks associated to this invasive procedure, including infection, thrombosis, and pneumothorax. The proposed pilot study will evaluate safety and preliminary efficacy of a new non-invasive ultrasound-based venous occlusion pressure (VOP) monitoring device (CPMX2) in children equipped with an invasive catheter for CVP monitoring as part of standard of care.",[26],"Central Venous Pressure",[28,29],"central venous pressure","venous hypertension","RECRUITING","2025-09-12",{"date":33,"type":34},"2025-09-18","ACTUAL",{"date":36,"type":34},"2025-03-10",{"date":38,"type":20},"2026-03-31",{"name":40,"class":41},"Compremium AG","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":42},"100534355","preoperative-sildenafil-administration-for-hepatectomy-100534355","NCT06237751","Preoperative Sildenafil Administration for Hepatectomy","Inclusion Criteria:\n\n* Patients undergoing hepatic resection\n* age from 18-85 years\n* Child-Pugh ≤B\n* ASA II-III\n* willing to join the trial.\n\nExclusion Criteria:\n\n* Pregnancy or Lactation\n* Known Allergy to any Medications used in the Study\n* Hemoglobin (Hb) \\\u003C 90 g\u002FL\n* Body Mass Index (BMI) \\> 35 kg\u002Fm2 or \\\u003C 18 kg\u002Fm2\n* Hypertension \\> 180 mmHg\n* Renal Impairment (Creatinine, Cr 178 µmol\u002FL)\n* Severe Cardiovascular Diseases including Active Coronary Artery Disease, Severe Valve Stenosis and Hypertrophic Obstructive Cardiomyopathy, History of Stroke Within Six Months.",true,"18 Years","85 Years",{"count":53,"type":20},16,[23],"Hepatectomy is an important treatment for liver diseases, and bleeding is one of the most common complications during dissection of the liver parenchyma. The Control Low Central Venous Pressure (CLCVP) technique is currently one of the most important techniques to control intraoperative bleeding. It mainly consists of fluid restriction, position adjustment, and the use of vasodilators. However, these measures focus on decreasing CVP by reducing the volume of return blood, and less attention is paid to factors such as pulmonary vascular resistance and cardiac function. Sildenafil, known as Viagra, is currently used to treat erectile dysfunction and pulmonary hypertension in men. Its action inhibits phosphodiesterase-5 (PDE-5) and increases cGMP levels, leading to smooth muscle relaxation and vasodilation. Its pharmacological properties provide potential value for the treatment of many diseases. However, few studies have been conducted both domestically and internationally on the use of sildenafil citrate in liver resection related to CLCVP. This study aims to investigate the influence of preoperative oral administration of Sildenafil Citrate combined with IPM on IBL and surgical results during open or laparoscopic hepatectomy, as well as its safety and feasibility. It is expected to provide an innovative management optimization plan for reducing the bleeding in hepatectomy and to provide empirical support for the potential value of Sildenafil Citrate or Sildenafil-like drugs in improving the safety and quality of perioperative hepatectomy patients.",[26,57,58,59],"Hepatectomy","Hemodynamics Instability","Sildenafil",[61,57,62,63,64],"Sildenafil Citrate","Laparoscopy","Low central venous pressure","Study protocol","2024-06-25",{"date":67,"type":34},"2024-06-27",{"date":69,"type":34},"2024-02-01",{"date":71,"type":20},"2024-12-30",{"name":73,"class":74},"First People's Hospital of Chenzhou","OTHER"]